Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiota Alteration With Atorvastatin/Ezetimibe in ASCVD
NCT06784557Phase 4Recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ezetimibe in atherosclerotic cardiovascular disease (ASCVD), sponsored by Yonsei University. Started Feb 2024; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06784557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784557.